Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Raija Silvennoinen
- Target Recruit Count
- 120
- Registration Number
- NCT03376672
- Locations
- 🇫🇮
Kuopio University Hospital, Kuopio, Finland
🇫🇮Oulu University Hospital, Oulu, Finland
🇫🇮Päijät-Häme Central Hospital, Lahti, Finland
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT03373305
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL
- Conditions
- Interventions
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT03367143
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, Shanghai, China
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Brian Jonas
- Target Recruit Count
- 4
- Registration Number
- NCT03359460
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Yvonne Efebera
- Target Recruit Count
- 1
- Registration Number
- NCT03333746
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Conditions
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 475
- Registration Number
- NCT03319667
- Locations
- 🇺🇸
Investigational Site Number: 8400006, Fort Myers, Florida, United States
🇺🇸Investigational Site Number: 8400004, Saint Petersburg, Florida, United States
🇺🇸Investigational Site Number: 8400007, Kansas City, Missouri, United States
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
- Conditions
- Interventions
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT03314636
- Locations
- 🇸🇪
Skåne University Hospital, Lund, Sweden
🇩🇰Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT03290950
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
- Conditions
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- International Myeloma Foundation
- Target Recruit Count
- 87
- Registration Number
- NCT03289299
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03283046
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.